S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
The 3-Stock Retirement Blueprint (Ad)
This Is Why Daktronics Fell 40% In One Day 
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
Why Your IRA Could Crash on January 16th? (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
Why Your IRA Could Crash on January 16th? (Ad)
Are Investors Hearing The End Of Spotify's Downtrend?
Is It Time To Throw In The Towel On Gamestop?

Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

$28.69
+0.76 (+2.72%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.26
$28.71
50-Day Range
$25.69
$31.52
52-Week Range
$16.75
$36.08
Volume
343,801 shs
Average Volume
633,735 shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.33

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
85.9% Upside
$53.33 Price Target
Short Interest
Bearish
11.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.55) to ($6.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

484th out of 1,022 stocks

Pharmaceutical Preparations Industry

213th out of 499 stocks

AGIO stock logo

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

Agios to Participate in December Investor Conference
SVB Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO)
Agios Pharmaceuticals: A Big Year On The Horizon
Agios Appoints Cecilia Jones as Chief Financial Officer
Agios Pharmaceuticals Gets CHMP Backing for Pyrukynd
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Company Calendar

Last Earnings
11/03/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
390
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.33
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+85.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$1.60 billion
Pretax Margin
-3,694.98%

Debt

Sales & Book Value

Annual Sales
$203.20 million
Book Value
$23.79 per share

Miscellaneous

Free Float
52,483,000
Market Cap
$1.58 billion
Optionable
Optionable
Beta
1.01

Key Executives

  • Dr. Bruce D. Car DACVP (Age 61)
    Ph.D., Consultant
    Comp: $776.12k
  • Dr. Sarah Gheuens M.D. (Age 42)
    Ph.D., Chief Medical Officer and Head of R&D
    Comp: $1.57M
  • Ms. Richa Poddar (Age 40)
    Chief Commercial Officer
    Comp: $624.08k
  • Mr. Brian M. Goff M.B.A. (Age 53)
    CEO & Director
  • Dr. Lewis Clayton Cantley Ph.D. (Age 73)
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Tak Wah Mak D.Sc. (Age 76)
    FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Craig B. Thompson M.D. (Age 69)
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Shin-San Su Ph.D. (Age 66)
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Cecilia Jones (Age 47)
    Chief Financial Officer
  • Mr. T. J. Washburn Jr. (Age 41)
    Principal Accounting Officer













AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price forecast for 2023?

6 equities research analysts have issued 12 month price targets for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $32.00 to $96.00. On average, they anticipate the company's stock price to reach $53.33 in the next year. This suggests a possible upside of 85.9% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2022?

Agios Pharmaceuticals' stock was trading at $32.87 at the beginning of the year. Since then, AGIO stock has decreased by 12.7% and is now trading at $28.69.
View the best growth stocks for 2022 here
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our AGIO earnings forecast
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) posted its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($1.49) EPS for the quarter, beating analysts' consensus estimates of ($1.71) by $0.22. The biopharmaceutical company had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.24 million. During the same period last year, the business earned ($1.48) earnings per share.

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.51%), BlackRock Inc. (8.72%), Bellevue Group AG (7.39%), State Street Corp (4.80%), First Trust Advisors LP (3.62%) and Armistice Capital LLC (3.50%). Insiders that own company stock include Carman Alenson, Christopher Bowden, Darrin Miles and Theodore James Jr Washburn.
View institutional ownership trends
.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $28.69.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.58 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.65) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

The company employs 390 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 12/9/2022 by MarketBeat.com Staff